Anti-PD-L1 antibody MPDL3280A is well-tolerated and associated with clinical activity in patients with metastatic bladder cancer, according to the results of a phase I study presented at ASCO. The objective response rate in 20 evaluable patients, measured using RECIST criteria, was 50% (one complete response, nine partial responses), with a median time to response of 43 days. Patients who progressed had higher levels of IL8 and CCL2 in their tumours prior to treatment.
References
Powles, T. et al. Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC) [abstract]. J. Clin. Oncol. 32 (Suppl.), 5011 (2014)
Rights and permissions
About this article
Cite this article
Promising results for immunotherapy drug. Nat Rev Urol 11, 364 (2014). https://doi.org/10.1038/nrurol.2014.153
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2014.153